We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.675 | 4.36 | 4.99 | - | 33,133 | 08:00:27 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.53 | 9.41M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 10/9/2020 08:06 | Given US investors between them bought over accumulated over 10% of the co and a fair whack at 200p I'm sure when the CEO alluded to international investors he was referring to those and others. I don't think access to funding will be an issue. Govs will also put their hands in their pockets and are throwing money at therapies and testing. I suspect a partner will come on bars though and given both data sets but who knows a regulator (anywhere) may approve and get things moving rapidly. | tickboo | |
| 09/9/2020 23:50 | redTicke wontSave yerLife dripDrop shlingShlong groundhog day ahead happyDreaming | andymunchkin |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
